scientists suggest that diabetes drugs has the ability to prevent and cure heart failure

For the first time, research shows that a type
2 diabetes drug significantly reduces
hospitalizations and death from heart failure.
The findings, from a large clinical trial known
as EMPA-REG OUTCOME, were presented by
Yale professor of medicine and clinical chief of
endocrinology, Dr. Silvio E. Inzucchi, at the
2015 American Heart Association (AHA)
Scientific Session in Orlando, Florida on Nov.
Many individuals with type 2 diabetes also
have heart failure, a condition in which the
heart fails to pump blood effectively.
Treatment for heart failure is limited and prior
efforts to treat patients with type 2 diabetes
drugs showed no benefit for heart failure. But
a new class of type 2 diabetes drugs (SGLT2
inhibitors) that reduce blood sugar by
increasing its excretion in the urine had not
been studied.
In the EMPA-REG trial, patients with type 2
diabetes and risk factors for heart disease
were randomized to receive once-daily doses
of either the glucose-lowering drug
empagliflozin (10 mg or 25 mg doses), or a
placebo. The drug or placebo was given in
addition to standard care.
At the end of the trial period, investigators
found that patients treated with the drug
experienced reductions in blood sugar and
blood pressure, as well as weight loss,
compared to those on placebo. They also
found major significant reductions in
hospitalizations for heart failure (35%); the
combined result for heart failure
hospitalization or dying from heart disease
(34%); and the combined result for being
hospitalized or dying from heart failure (39%).
Additionally, Inzucchi and his colleagues
analyzed outcomes for subgroups of patients
who had heart failure at the beginning of the
trial and those who did not. “We found that
reductions in the hospitalization outcomes
were similar between the two subgroups,” he
said. “So, one conclusion that could be
proposed is that the drug not only appeared
to prevent deterioration in patients who
already had heart failure but also appeared to
prevent that condition from developing in
patients who never had it before.”

Author: TheGoldendiamond

Follow Us on Instagram **** Twitter **** Youtube **** Facebook **** Contact Us ***** google+

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s